The Effect of Diabetes on Oxaliplatin-Induced Peripheral Neuropathy

Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients

“…Cumulative OXA dose is a well-recognised factor associated with a higher incidence and severity of chronic neuropathy 12 20 25. In contrast with other studies that did not find gender predominance,26 27 we found a male predominance that could be explained by the fact that men usually present a higher body mass index, therefore receiving higher OXA total cumulative doses (men 1717.53±263.04 mg vs women 1548.23±286.78 mg, p<0.001).…”

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

“…The relationship with age is consistent with several previous reports of taxane-induced neuropathy, including ECOG 5103 (4, 8, 36). In contrast, a number of studies of oxaliplatin-treated patients did not find an association with age (6, 7). …”

“…The authors of one study that found a correlation between smoking and CIPN postulated that long-term heavy smoking reduces peripheral blood flow, likely exacerbating paclitaxel-induced neuropathy (5). Conversely, a study of 730 TCS given platinum-based chemotherapy (9) and another of 62 colon cancer patients receiving oxaliplatin reported no association (7). Among 169 patients given oxaliplatin-based chemotherapy, alcohol consumption was associated with neuropathy (6).…”

Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study

“…Although these associations seem plausible, because such conditions can cause a neuropathy similar to CIPN, their role as risk factors for CIPN is not yet demonstrated since most previous investigations excluded these patients and the few existing studies have conflicting results [15][16][17][18] and, to our knowledge, the available results do not refer specifically to breast cancer patients.…”